Education
About Us
Working with TipRanks
Follow Us
RegenXBio Inc. (RGNX)
:RGNX
RGNX Stock Chart & Stats
$11.73
-$0.26(-3.11%)
At close: 4:00 PM EST
$11.73
-$0.26(-3.11%)
Day’s Range― - ―
52-Week Range$5.04 - $12.99
Previous CloseN/A
Volume155.59K
Average Volume (3M)566.91K
Market Cap
$623.35M
Enterprise Value$371.07M
Total Cash (Recent Filing)$323.30M
Total Debt (Recent Filing)$271.69M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Nov 05, 2025EPS Estimate
-1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding50,514,217
10 Day Avg. Volume709,219
30 Day Avg. Volume566,910
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue2.38
Enterprise Value/Gross Profit2.98
Enterprise Value/Ebitda-2.86
Forecast
1Y Price Target
$25.67Price Target Upside118.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesRGX-121 exhibited sustained reductions in CSF HS D2S6 with a median reduction of 82% at 1 year.
Commercial OpportunitiesREGENXBIO would lead commercial manufacturing and supply chain and receive double-digit royalties on net sales in the U.S. and Asia as well as milestone payments.
Regulatory SupportRGX-121 has received multiple designations from the FDA, including Orphan Drug and Fast Track, indicating strong regulatory support.
Bears Say
Commercial ProspectsShare impact will likely be muted as commercial opportunity in MPS II is modest and RGNX monetized the majority of its economic interest through strategic partnership with Nippon Shinyaku.
Regulatory DelaysFDA extended BLA review of clemidsogene lanparvovec (RGX-121) for Mucopolysaccharidosis II, pushing the PDUFA date to February 8, 2026.
RegenXBio News
RGNX FAQ
What was RegenXBio Inc.’s price range in the past 12 months?
RegenXBio Inc. lowest stock price was $5.04 and its highest was $12.99 in the past 12 months.
What is RegenXBio Inc.’s market cap?
RegenXBio Inc.’s market cap is $623.35M.
When is RegenXBio Inc.’s upcoming earnings report date?
RegenXBio Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 18 days.
How were RegenXBio Inc.’s earnings last quarter?
RegenXBio Inc. released its earnings results on Aug 07, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.938 by -$0.442.
Is RegenXBio Inc. overvalued?
According to Wall Street analysts RegenXBio Inc.’s price is currently Undervalued.
Does RegenXBio Inc. pay dividends?
RegenXBio Inc. does not currently pay dividends.
What is RegenXBio Inc.’s EPS estimate?
RegenXBio Inc.’s EPS estimate is -1.3.
How many shares outstanding does RegenXBio Inc. have?
RegenXBio Inc. has 50,514,217 shares outstanding.
What happened to RegenXBio Inc.’s price movement after its last earnings report?
RegenXBio Inc. reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.938. Following the earnings report the stock price went down -4.01%.
Which hedge fund is a major shareholder of RegenXBio Inc.?
Currently, no hedge funds are holding shares in RGNX
RegenXBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.67 (118.84% Upside)
$25.67 (118.84% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 58.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 15.8%
Last 30 Days ▲ 15.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.66%
12-Months-Change
Fundamentals
Return on Equity
-62.49%
Trailing 12-Months
Asset Growth
2.05%
Trailing 12-Months
Company Description
RegenXBio Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
RGNX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong clinical progress and strategic partnerships. However, uncertainties around regulatory processes and competitive pressures create some challenges. The company is well-positioned financially and operationally to advance its pipeline.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$25.67
▲(118.84% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
Opthea Limited Sponsored ADR
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
8.70% Insiders
19.54% Mutual Funds
1.51% Other Institutional Investors
56.91% Public Companies and Individual Investors